Lantheus doses first patient in SPARROW Phase 2/3 prostate cancer imaging trial for LNTH-2401
Bitget2026/09/28 12:04- Lantheus dosed the first patient in SPARROW, a Phase 2/3 registrational study of LNTH-2401 PET imaging in prostate cancer.
- No clinical results were presented; the trial is designed to generate data for a future diagnostic performance readout.
- The study aims to show LNTH-2401 can help detect and characterize prostate cancer using a GRPR-targeted approach complementary to PSMA imaging.
- Phase 3 is expected to enroll about 400 participants, positioning the program as a potential pipeline expansion in prostate cancer imaging.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The British Pound rallies on a UK growth upgrade and gives more than half back
Only twice in history! S&P 500 equal-weight index is expected to record seven consecutive weeks of decline this week
The S&P 500 Equal Weight Index is expected to fall for a seventh consecutive week. If this downward trend continues through Friday, it will mark only the third time in history that the index has experienced seven straight weeks of decline.
Trump “bites” Powell, demanding his resignation from the Federal Reserve Board, citing severe cost overruns in headquarters renovation.
U.S. President Trump on Wednesday called for former Federal Reserve Chairman Powell to resign from his position as a Fed governor, following an inspector general report on the Federal Reserve headquarters renovation project, which highlighted a series of management issues that led to significant cost overruns.
Crypto prices
More
